RDNT Quote, Financials, Valuation and Earnings

Guardant Health has a net margin of -8.05% compared to RadNet's net margin of -46.77%. RadNet's return on equity of -2.91% beat Guardant Health's return on equity of -8518.58%.

RadNet has a consensus price target of $71.57, signalling upside risk potential of 27.25%. On the other hand Guardant Health has an analysts' consensus of $59.43 which suggests that it could grow by 21.25%. Given that RadNet has higher upside potential than Guardant Health, analysts believe RadNet is more attractive than Guardant Health.

RadNet has a beta of 1.429, which suggesting that the stock is 42.944% more volatile than S&P 500. In comparison Guardant Health has a beta of 1.373, suggesting its more volatile than the S&P 500 by 37.333%.

RadNet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guardant Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RadNet pays -- of its earnings as a dividend. Guardant Health pays out -- of its earnings as a dividend.

RadNet quarterly revenues are $471.4M, which are larger than Guardant Health quarterly revenues of $203.5M. RadNet's net income of -$37.9M is higher than Guardant Health's net income of -$95.2M. Notably, RadNet's price-to-earnings ratio is 1,513.25x while Guardant Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RadNet is 2.30x versus 7.81x for Guardant Health. Usually stocks with elevated PS ratios are considered overvalued.

iSpecimen has a net margin of -8.05% compared to RadNet's net margin of -156.82%. RadNet's return on equity of -2.91% beat iSpecimen's return on equity of -249.02%.

RadNet has a consensus price target of $71.57, signalling upside risk potential of 27.25%. On the other hand iSpecimen has an analysts' consensus of -- which suggests that it could grow by 5209.74%. Given that iSpecimen has higher upside potential than RadNet, analysts believe iSpecimen is more attractive than RadNet.

RadNet has a beta of 1.429, which suggesting that the stock is 42.944% more volatile than S&P 500. In comparison iSpecimen has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

RadNet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iSpecimen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RadNet pays -- of its earnings as a dividend. iSpecimen pays out -- of its earnings as a dividend.

RadNet quarterly revenues are $471.4M, which are larger than iSpecimen quarterly revenues of $1.1M. RadNet's net income of -$37.9M is lower than iSpecimen's net income of -$1.7M. Notably, RadNet's price-to-earnings ratio is 1,513.25x while iSpecimen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RadNet is 2.30x versus 0.18x for iSpecimen. Usually stocks with elevated PS ratios are considered overvalued.

Labcorp Holdings has a net margin of -8.05% compared to RadNet's net margin of 6.36%. RadNet's return on equity of -2.91% beat Labcorp Holdings's return on equity of 9.01%.

RadNet has a consensus price target of $71.57, signalling upside risk potential of 27.25%. On the other hand Labcorp Holdings has an analysts' consensus of $274.62 which suggests that it could grow by 4.96%. Given that RadNet has higher upside potential than Labcorp Holdings, analysts believe RadNet is more attractive than Labcorp Holdings.

RadNet has a beta of 1.429, which suggesting that the stock is 42.944% more volatile than S&P 500. In comparison Labcorp Holdings has a beta of 0.812, suggesting its less volatile than the S&P 500 by 18.757%.

RadNet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Labcorp Holdings offers a yield of 1.1% to investors and pays a quarterly dividend of $0.72 per share. RadNet pays -- of its earnings as a dividend. Labcorp Holdings pays out 32.59% of its earnings as a dividend. Labcorp Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

RadNet quarterly revenues are $471.4M, which are smaller than Labcorp Holdings quarterly revenues of $3.3B. RadNet's net income of -$37.9M is lower than Labcorp Holdings's net income of $212.8M. Notably, RadNet's price-to-earnings ratio is 1,513.25x while Labcorp Holdings's PE ratio is 30.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RadNet is 2.30x versus 1.67x for Labcorp Holdings. Usually stocks with elevated PS ratios are considered overvalued.

23andMe Holding has a net margin of -8.05% compared to RadNet's net margin of --. RadNet's return on equity of -2.91% beat 23andMe Holding's return on equity of --.

RadNet has a consensus price target of $71.57, signalling upside risk potential of 27.25%. On the other hand 23andMe Holding has an analysts' consensus of -- which suggests that it could fall by -59.61%. Given that RadNet has higher upside potential than 23andMe Holding, analysts believe RadNet is more attractive than 23andMe Holding.

RadNet has a beta of 1.429, which suggesting that the stock is 42.944% more volatile than S&P 500. In comparison 23andMe Holding has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

RadNet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 23andMe Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RadNet pays -- of its earnings as a dividend. 23andMe Holding pays out -- of its earnings as a dividend.

RadNet quarterly revenues are $471.4M, which are larger than 23andMe Holding quarterly revenues of --. RadNet's net income of -$37.9M is higher than 23andMe Holding's net income of --. Notably, RadNet's price-to-earnings ratio is 1,513.25x while 23andMe Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RadNet is 2.30x versus 0.62x for 23andMe Holding. Usually stocks with elevated PS ratios are considered overvalued.